| scholarly article | Q13442814 |
| P50 | author | Robert J H Miller | Q79426218 |
| P2093 | author name string | Matthew T James | |
| Stephen B Wilton | |||
| Merril Knudtson | |||
| Bing Li | |||
| Jonathan G Howlett | |||
| Michael H Chiu | |||
| Rebecca Barry | |||
| Bryan J Har | |||
| P2860 | cites work | Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease | Q24235834 |
| A new equation to estimate glomerular filtration rate | Q24651973 | ||
| Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study | Q28167204 | ||
| The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease | Q28171188 | ||
| Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Q34246898 | ||
| Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis | Q34380599 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction | Q35640412 | ||
| Prevalence and prognostic impact of kidney disease on heart failure patients | Q36517260 | ||
| The frequency of hyperkalemia and its significance in chronic kidney disease. | Q36530203 | ||
| Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease | Q36598162 | ||
| Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System | Q36896690 | ||
| Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study | Q37017442 | ||
| Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis | Q37066505 | ||
| Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril | Q37528075 | ||
| Pharmacologic therapy in patients with chronic heart failure and chronic kidney disease: a complex issue | Q37587115 | ||
| Cardiorenal syndrome: new perspectives | Q37765094 | ||
| Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. | Q40116112 | ||
| Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study | Q40280356 | ||
| Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. | Q40464648 | ||
| Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. | Q43576144 | ||
| Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications | Q44169479 | ||
| Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Q44588075 | ||
| High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database | Q46162624 | ||
| Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit | Q46318699 | ||
| Kidney function and mortality among patients with left ventricular systolic dysfunction. | Q46807791 | ||
| 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure | Q47374177 | ||
| Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? | Q50657801 | ||
| Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. On behalf of the APPROACH investigators. | Q53509007 | ||
| The perindopril in elderly people with chronic heart failure (PEP-CHF) study | Q61716699 | ||
| Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction | Q73256719 | ||
| Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function | Q74352999 | ||
| Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease | Q80410768 | ||
| Epidemiology of heart failure | Q87330478 | ||
| Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction | Q87736820 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| hospitalization | Q3140971 | ||
| P304 | page(s) | 2054358118804838 | |
| P577 | publication date | 2018-10-15 | |
| P1433 | published in | Canadian journal of kidney health and disease | Q27726098 |
| P1476 | title | Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study | |
| P478 | volume | 5 |
Search more.